In breast cancer, Zhang et al. revealed that HK2 enhances glycolysis through the ROS/PI3K/AKT pathway, and inhibiting HK2 lowered ROS levels, improving the efficacy of cancer treatments 168. This evidence concerns the gene HK2 and breast carcinoma.